Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T2 RelaxometryBurgetova A.a · Seidl Z.a, c · Krasensky J.a · Horakova D.b · Vaneckova M.a
Departmentsof aRadiology and bNeurology, First Faculty of Medicine, General Teaching Hospital, Charles University in Prague, and cMedical College, Prague, Czech Republic
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
The aim of this work was to quantify the accumulation of iron in the basal ganglia in multiple sclerosis (MS) patients and in a control group, and to investigate the relationship between iron accumulation and other parameters assessed in MS, i.e. lesion load (LL) and brain parenchymal fraction (BPF). Magnetic resonance imaging T2 relaxometry was used for the measurement. 970 patients with clinically definite MS and 117 controls were examined. Patients were divided into three subgroups according to LL and BPF. This work provides quantitative evidence of increased iron accumulation in the basal ganglia in MS patients in comparison to healthy controls. We also found that in the subgroup with small LL value, iron accumulation is higher than in the subgroup with large LL value. The hypothesis of a neurodegenerative component of MS is supported by the changes in iron content in the brain.
© 2010 S. Karger AG, Basel
- Bakshi R, Minagar A, Jaisani Z, Wolinsky JS: Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2005;2:277–303.
- Drayer BP, Burger P, Hurwitz B, Dawson B, Cain J, Leong J, Herfkens R, Johnson GA: Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann Neurol 1987;22:546–550.
- Grimaud J, Millar J, Thorpe JW, Moseley IF, McDonald WI, Miller DH: Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:306–308.
- Bakshi R, Shaikh ZA, Janardhan V: MRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation. NeuroReport 2000;11:15–21.
- Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L: Gray matter hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001;185:19–26.
- Bermel RA, Puli SR, Rudick RA, Weinstock-Guttman B, Fisher E, Munschauer FE 3rd, Bakshi R: Gray matter MRI hypointensity predicts longitudinal brain atrophy in multiple sclerosis. Arch Neurol 2005;62:1371–1376.
- Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R: Cognitive impairment is associated with subcortical magnetic resonance imaging gray matter T2 hypointensity in multiple sclerosis. Mult Scler 2006;12:437–444.
- Gutteridge JM: Iron and oxygen radicals in brain. Ann Neurol 1992;32:S16–S21.
- Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J: Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350–354.
- Hallgren B, Sourander P: The effect of age on the non-haemin iron in the human brain. J Neurochem 1958;3:41–51.
Fiehring H, Sundermann A: Ferritin in the normal human brain (German). Z Gesamte Inn Med 1986;14:787–790.
- Pujol J, Juque C, Vendrell P, Grau JM. Martí-Vilalta JL, Olivé C, Gili J: Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch Neurol 1992;49:711–717.
- Moos T, Morgan EH: The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann NY Acad Sci 2004;1012:14–26.
- Drayer B, Burger P, Hurwitz B, Dawson D, Cain J: Reduced signal intensity on MR Images of thalamus and putamen in multiple sclerosis: increased iron content? AJR Am J Roentgenol 1987;357–363.
- Schenker C, Meier D, Wichmann W, Boesiger P, Valavanis A: Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology 1993;35:119–124.
Vaneckova M, Seidl Z, Krasensky J, Obenberger J, Havrdova E, Vitak T, Danes J: Sledování objemu ložisek u roztroušené sklerózy mozkomíšní magnetickou rezonancí (MRI study of lesion load in multiple sclerosis) (in Czech). Ces a Slov Neurol Neurochir 2002;3:175–179.
- Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW, Fabiano AJ, Jacobs L: T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002;59:62–68.
- Connor CR, Snyder BS, Beard JL, Fine RE, Mufson EJ: Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer‘s disease. J Neurosci Res 1992;31:327–335.
- Smith MA, Perry G: Free radical damage, iron, and Alzheimer’s disease. J Neurol Sci 1995;134(suppl):S92–S94.
- Youdim MBH, Ben-Shachar D, Riederer P: Iron in brain function and dysfunction with emphasis on Parkinson’s disease. Eur Neurol 1991;31(suppl 1):34–40.
- Berg D, Hochstrasser H: Iron metabolism in parkinsonian syndromes. Mov Disord 2006;21:1299–1310.
Hirsch EC, Faucheus BA: Iron metabolism and Parkinson‘s disease. Mov Disord 1998;13(suppl 1):S39–S45.
- Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J: Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569–574.
- Pearce JMS: Neurodegeneration with brain iron accumulation: a cautionary tale. Eur Neurol 2006;56:66–68.
- Kabuto H, Yokoi I, Ogawa N: Melatonin inhibits iron-induced epileptic discharges in rats suppressing peroxidation. Epilepsia 1998;39:237–243.
Schenck JF, Zimmerman EA: High field magnetic resonance imaging of brain iron: birth of a biomarker? MNR Biomed 2004;17:433–445.
- Bermel RA, Innus MD, Tjoa CV, Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport 2003;14:335–339.
- Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM: Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650–653.
Gossuin Y, Burtea C, Monseaux A, Toubeau G, Roch A, Muller RN, Gillis P: Ferritin-induced relaxation in tissues: an in vitro study. J Magn Reson Imaging 2004;20690–20696.
- Metafratzi Z, Argyropoulou MI, Kiortsis DN, Tsampoulas C, Chaliassos N, Efremidis SC: T2 relaxation rate of basal ganglia and cortex in patients with thalassemia major. Br J Radiol 2001;74:407–410.
- Bartzokis G, Tishler TA, Lu PH, Villablanca P, Altushuler LL, Carter M, Huang D, Edwards Nm Mintz J: Brain ferritin iron may influence age-and gender-related risks of neurodegeneration. Neurobiol Aging 2007;28:414–423.
- Péran P, Cherubini A, Luccichenti G, Hagberg G, Gémonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, Sabatini U: Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp 2009;30:2667–2675.
- Neema M, Stankiewicz J, Arora A, Dandamudi VSR, Batt CE, Guss ZD, Al-Sabbagh A, Bakshi R: T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 2007;17(suppl 1):16S–21S.
- Vaneckova M, Seidl Z, Krasensky J, Havrdova E, Horakova D, Dolezal O, Burgetova A, Masek M: Patients’ stratification and correlation of brain MRI parameters to disability progression in multiple sclerosis. Eur Neurol 2009;61:278–284.
- Bowern N, Ramshaw I, Clark I, Doherty PC: Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 1984;160:1532–1543.
- Willenborg DO, Bowern N, Danta G, Doherty PC: Inhibition of allergic encephalomyelitis by the iron-chelating agent desferrioxamine: differential effect depending on type sensitizing encephalitogen. J Neuroimmunol 1988;17:127–135.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.